Hudock Inc. Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

Hudock Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,249 shares of the biopharmaceutical company’s stock after selling 1,570 shares during the quarter. Hudock Inc.’s holdings in Pfizer were worth $1,367,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Court Place Advisors LLC boosted its stake in shares of Pfizer by 9.7% during the third quarter. Court Place Advisors LLC now owns 31,754 shares of the biopharmaceutical company’s stock valued at $919,000 after purchasing an additional 2,807 shares in the last quarter. Burke & Herbert Bank & Trust Co. grew its stake in Pfizer by 1.8% during the 3rd quarter. Burke & Herbert Bank & Trust Co. now owns 77,728 shares of the biopharmaceutical company’s stock valued at $2,249,000 after purchasing an additional 1,345 shares during the last quarter. Canal Capital Management LLC raised its stake in shares of Pfizer by 1.7% during the 3rd quarter. Canal Capital Management LLC now owns 27,012 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 454 shares during the last quarter. Ballentine Partners LLC grew its stake in shares of Pfizer by 1.1% during the 3rd quarter. Ballentine Partners LLC now owns 108,861 shares of the biopharmaceutical company’s stock worth $3,150,000 after purchasing an additional 1,172 shares during the period. Finally, Coerente Capital Management lifted its stake in shares of Pfizer by 1.0% in the 3rd quarter. Coerente Capital Management now owns 589,052 shares of the biopharmaceutical company’s stock valued at $17,047,000 after purchasing an additional 5,989 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on PFE shares. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Citigroup initiated coverage on shares of Pfizer in a report on Friday. They issued a “neutral” rating and a $30.00 price target for the company. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Wells Fargo & Company boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Trading Up 0.1 %

Shares of NYSE PFE traded up $0.04 during trading on Friday, hitting $28.68. 2,073,833 shares of the company were exchanged, compared to its average volume of 36,733,469. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a fifty day moving average price of $29.07 and a 200-day moving average price of $28.48. The firm has a market capitalization of $162.52 billion, a PE ratio of -62.28, a P/E/G ratio of 1.01 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.86%. Pfizer’s dividend payout ratio (DPR) is -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.